Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GenesisCare USA
The Registry will collect information on key clinical indications and patient reported outcomes to assess the safety and efficacy of VMAT radiotherapy. Data that will be collected includes baseline data of demographic, relevant medical history, photographs, treatment schedule, and treatment outcomes. Data may be collected retrospectively in regard to previous relevant medical history, prior treatments and outcomes as well as prospectively, including treatment schedule and treatment outcomes of radiotherapy treatment.
The Registry aims to assess the safety and outcomes of treatment for up to 5 years. This Registry will be the first of its kind in the US and will provide a basis for a number of potential research publications. The Registry will also give insights into treatment delivery and potentially facilitate future improvements in patient care.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Over 18 years of age
Diagnosed with a treatable non-melanoma skin cancer by referring medical practitioner
Eligible to be treated using widefield (\>50cm2) VMAT radiotherapy as determined by RO
Patient has provided written informed consent.
You may not be if
♦ Patients who do not consent to their involvement in the Registry.